BPC-157 Peptide

Product Specifications

CAS: 137525-51-0

Also Known As: Body Protection Compound-157, BPC 157, PL-10, Pentadecapeptide BPC 157

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Molecular Formula: C₆₂H₉₈N₁₆O₂₂

Molecular Weight: 1419.55 Da

Purity: 99%+ (verified by HPLC)

Appearance: White to off-white lyophilized powder

Form: Lyophilized (freeze-dried)

Classification: Synthetic pentadecapeptide, partial sequence of human gastric BPC protein

Storage

BPC-157 vials must be stored in a cool, dry place away from direct sunlight. Unreconstituted BPC 157 peptide should be kept at -20°C for long-term storage or 2-8°C for short-term storage (up to 3 months). Once reconstituted with bacteriostatic water, BPC-157 should be refrigerated at 2-8°C and used within 28-30 days for optimal stability. Do not freeze reconstituted solutions. Always follow proper aseptic technique and storage guidelines to maintain product integrity for research applications.

Solubility

BPC-157 is freely soluble in bacteriostatic water and sterile saline. Recommended reconstitution concentration is 0.5-2 mg/mL. Gently swirl the vial after adding solvent. Do not vortex or shake vigorously, as this may damage the peptide structure. BPC 157 is notably stable in acidic aqueous conditions, including simulated gastric fluid, which underlies research into oral BPC-157 administration.

Intended Use

BPC-157 is intended for research purposes only and is not approved for human use.

What Is BPC-157? Mechanism of Action, VEGF Upregulation, and Angiogenesis

• BPC-157 is a synthetic 15-amino-acid peptide (pentadecapeptide) derived from a region of the body protection compound protein naturally present in human gastric juice. What is BPC-157 used for in preclinical science? Research centres on its ability to activate multiple overlapping repair pathways simultaneously, rather than acting on a single receptor or signalling molecule.
• What does BPC 157 do at the molecular level? Studies show BPC-157 significantly upregulates vascular endothelial growth factor (VEGF), promoting the formation of new blood vessels (angiogenesis) at injury sites. This increased vascularity delivers oxygen and nutrients to damaged tissue, creating the conditions required for accelerated cellular repair. BPC-157 also activates the FAK-paxillin pathway and stimulates nitric oxide production via eNOS, driving cell migration toward wound sites.
• Is BPC-157 safe? Preclinical safety data from studies in mice, rats, rabbits, and dogs show BPC 157 is well tolerated across a broad dose range. No genotoxicity, embryo-fetal toxicity, or organ toxicity was identified. BPC 157 side effects in preclinical research have been minimal, supporting a favourable safety profile that underpins continued investigation. Is BPC 157 legal? As a research compound, BPC-157 is not a controlled substance and is legally available for laboratory research purposes.

BPC-157 Benefits for Wound Healing, Tendon Repair, and BPC 157 Before and After Research

• BPC 157 peptide benefits for musculoskeletal repair are among the most extensively documented effects in the preclinical literature. In tendon transection models, BPC-157-treated subjects showed restoration of up to 87% of normal biomechanical tensile strength compared to untreated controls, with significantly increased collagen fibre density and organisation. Similar results have been observed in ligament and muscle tear models.
• BPC 157 before and after comparisons in wound healing studies consistently show accelerated reepithelialization, reduced inflammatory infiltration, and earlier formation of granulation tissue relative to controls. The peptide has also demonstrated efficacy in bone fracture repair models, stimulating osteoblast activity and promoting callus formation at earlier timepoints.
• BPC-157 benefits for gut repair are equally well supported. The peptide rapidly heals gastric ulcers induced by alcohol, NSAIDs, and corticosteroids in animal models, while reversing intestinal permeability defects (leaky gut) by upregulating tight junction proteins including occludin, claudin, and ZO-1. BPC 157 benefits for women and men in gastrointestinal and inflammatory research models are mechanistically equivalent, with no sex-specific differences identified in preclinical protocols. BPC 157 side effects in these models remain consistently low across both sexes.

BPC-157 and TB-500: Mechanisms Compared and Combined Use in Research

• BPC 157 vs TB-500 is one of the most commonly researched comparisons in regenerative peptide science. BPC-157 acts primarily through VEGF-driven angiogenesis, nitric oxide signalling, and direct mucosal cytoprotection, with particular effectiveness in tendon, ligament, and gastrointestinal tissue. TB-500 (thymosin beta 4) acts through actin sequestration and cell migration via the LKKTETQ motif, driving keratinocyte and stem cell movement toward injury sites with strong systemic and cardiac repair activity.
• BPC 157 and TB-500 are considered mechanistically complementary rather than redundant. TB 500 vs BPC 157 in head-to-head wound models shows additive effects when both are present, suggesting the two peptides engage different phases of the repair cascade: BPC-157 initiating vascular remodelling and mucosal protection, TB-500 accelerating cell migration and anti-inflammatory resolution.
• The BPC-157 and TB-500 combination is one of the most studied peptide pairings in preclinical tissue repair research. The BPC 157 TB 500 blend is examined across muscle, tendon, cardiac, and skin injury models. Research on BPC-157 TB-500 blend dosage and scheduling indicates staggered or concurrent administration may maximise the distinct vascular and migratory contributions of each peptide, though specific BPC-157 + TB-500 blend dosage calculator outputs depend on the animal model and tissue type under investigation.

BPC 157 Dosage for Research

The BPC 157 dosage used in preclinical research varies by study design, animal model, and administration route. Common dosing protocols in the published literature include:

• Subcutaneous injection: 1-10 mcg/kg body weight, the most common route for systemic and musculoskeletal research. This translates to approximately 90-900 mcg for a 90 kg research subject when calculating BPC-157 dosage per body weight. For a 200 lb (90 kg) research model, a mid-range BPC 157 dosage of 2.5-5 mcg/kg is most frequently represented in the published literature.
• Intraperitoneal injection: 10-100 mcg/kg body weight, used in gastrointestinal, inflammatory, and systemic studies where broader distribution is needed.
• Oral administration: 1-100 mcg/kg in water or saline. Oral BPC-157 exploits the peptide's notable stability in gastric acid, and is used specifically in GI-targeted protocols. Research into oral BPC 157 shows comparable efficacy to injection for intestinal permeability and ulcer healing endpoints.
• Topical / local injection: Applied directly to the injury site in tendon, ligament, and wound models. BPC 157 injection near the lesion consistently outperforms systemic routes in localised tissue repair studies.

BPC 157 dosage frequency in most research protocols is once daily, with study durations ranging from 7 to 30 days depending on the injury model and endpoint. A BPC 157 dosage chart for body weight-based calculations should use the 1-10 mcg/kg range as reference, though individual study parameters will vary. A BPC 157 dosage calculator can assist in scaling published mcg/kg doses to a given research subject weight.

How to Inject BPC-157 and Where to Inject BPC-157

In research protocols, BPC 157 injection is most commonly performed subcutaneously. How to inject BPC-157: the reconstituted peptide is drawn into a sterile insulin syringe and administered via subcutaneous injection using standard aseptic technique. Where to inject BPC 157 depends on the research objective: for localised tissue repair studies, injection near the injury site is preferred; for systemic or gastrointestinal endpoints, abdominal subcutaneous sites are most common in animal models. All injection procedures must be performed by qualified researchers under appropriate institutional guidelines.

BPC-157 and TB-500 Dosage in Combined Research Protocols

When BPC 157 and TB-500 are studied together, each peptide is typically dosed independently at its own published range rather than at a reduced combined dose. BPC 157 TB 500 dosage protocols in the literature use BPC-157 at 2-10 mcg/kg and TB-500 at 1-6 mg/kg concurrently or in alternating schedules. The BPC-157 + TB-500 blend dosage calculator approach divides the two compounds by their distinct mechanisms: BPC-157 for vascular/GI endpoints, TB-500 for cell migration/anti-inflammatory endpoints. BPC 157 TB 500 capsules formulations have been studied orally in some protocols, though injectable forms remain more common in the peer-reviewed literature.

Research Protocol Notes

BPC-157 is supplied as a lyophilized (freeze-dried) powder to ensure stability during transport and storage. For experimental protocols, the peptide must be reconstituted using a sterile solvent, most commonly bacteriostatic water or sterile saline. Introduce the diluent slowly down the side of the vial to prevent damaging the fragile peptide bonds. Do not shake vigorously. Reconstituted BPC-157 peptide solutions should be stored at 2-8°C and used within 28-30 days.